COLLIGO-HCM is a global observational study that will conduct observational research of hypertrophic cardiomyopathy (HCM) treatment in real-world clinical practice.
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Participant age at Hypertrophic Cardiomyopathy (HCM) diagnosis
Timeframe: Baseline, index date
Participant age at mavacamten treatment initiation
Timeframe: Index date
Participant sex
Timeframe: Baseline
Participant race/ethnicity
Timeframe: Baseline
Participant insurance coverage
Timeframe: Baseline
Participant employment status
Timeframe: Baseline
Participant educational level
Timeframe: Baseline
Date of Hypertrophic Cardiomyopathy (HCM) diagnosis
Timeframe: Baseline or index date
Participant body mass index (BMI) at Hypertrophic Cardiomyopathy (HCM) diagnosis
Timeframe: Baseline or index date
Hypertrophic Cardiomyopathy (HCM) subtype at diagnosis
Timeframe: Baseline or index date
Participant echocardiogram (ECHO) parameters at Hypertrophic Cardiomyopathy (HCM) diagnosis
Timeframe: Baseline or index date, and up to 33 months
Participant New York Heart Association (NYHA) class
Timeframe: Baseline or index date, and up to 33 months
Reason/trigger for initiating the path to Hypertrophic Cardiomyopathy (HCM) diagnosis
Timeframe: Baseline
Date of reason/trigger that initiated the path to Hypertrophic Cardiomyopathy (HCM) diagnosis
Timeframe: Baseline
Participant height
Timeframe: Baseline
Participant weight
Timeframe: Baseline
Participant blood pressure
Timeframe: Baseline
Participant heart rate
Timeframe: Baseline
Participant Hypertrophic Cardiomyopathy (HCM) symptoms
Timeframe: Baseline or index date, and up to 33 months
European participant CYP2C19 genotype
Timeframe: Baseline or index date, and up to 33 months
Participant family history of Hypertrophic Cardiomyopathy (HCM)
Timeframe: Baseline or index date
Participant family history of obstructive Hypertrophic Cardiomyopathy o(HCM)
Timeframe: Baseline or index date
Participant family history of sudden cardiac death (SCD)
Timeframe: Baseline or index date
Participant smoking status
Timeframe: Baseline or index date
Participant alcohol use
Timeframe: Baseline or index date
Participant recreational drug use
Timeframe: Baseline or index date
Participant involvement in a Hypertrophy Cardiomyopathy (HCM) randomized clinical trial (RCT)
Timeframe: Baseline or index date, and up to 33 months
Participant cardiovascular (CV) and CV-related comorbidities
Timeframe: Baseline and index date
Participant non-cardiovascular (CV)-related comorbidities
Timeframe: Baseline or index date
Participant electrocardiogram (ECG) rhythm results
Timeframe: Baseline or index date
Participant cardiac magnetic resonance imaging (MRI) results
Timeframe: Baseline or index date
Participant N-terminal pro-B-type natriuretic peptide (NT-proBNP) results
Timeframe: Baseline or index date
Participant cardiac troponin results
Timeframe: Baseline or index date
Participant cardiopulmonary exercise test (CPET) results
Timeframe: Baseline or index date
Participant cardiac monitoring results
Timeframe: Baseline or index date
Participant exercise test results
Timeframe: Baseline or index date
Participant blood creatine levels
Timeframe: Baseline or index date
Participant cardiovascular (CV) events
Timeframe: Baseline
Type of procedures received by participants
Timeframe: Baseline or index date, and up to 33 months
Cardiovascular treatments prescribed to participants
Timeframe: Baseline, and up to 33 months
Date of mavacamten prescription
Timeframe: Baseline
Date of mavacamten treatment initiation
Timeframe: Index date
Date of mavacamten dosage change
Timeframe: Up to 33 months
Reason for mavacamten dosage change
Timeframe: Up to 33 months
Occurrence of mavacamten stable dose (a period of 6-months with the same dose)
Timeframe: Up to 33 months
Dates of follow-up after mavacamten treatment initiation
Timeframe: Up to 33 months
Date of mavacamten treatment interuption or discontinuation
Timeframe: Up to 33 months
Reason for mavacamten treatment interuption or discontinuation
Timeframe: Up to 33 months
Supportive care provided to participants
Timeframe: Up to 33 months
Heath care resource utilization (HCRU)
Timeframe: Up to 33 months
Hypertrophic Cardiomyopathy (HCM) symptom improvement post mavacamten treatment initiation
Timeframe: Up to 33 months